179692-08-1

Usage

Uses

Used in Organic Synthesis:
Ethyl 4-iodo-1H-pyrazole-5-carboxylate is utilized as a key intermediate in organic synthesis for the preparation of a variety of chemical compounds. Its unique structural features and reactivity make it a versatile component in the synthesis of complex organic molecules.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, Ethyl 4-iodo-1H-pyrazole-5-carboxylate is employed as a building block for the development of new pharmaceuticals. Its structural properties allow for the creation of compounds with potential therapeutic applications.
Used in the Synthesis of Pharmacologically Active Compounds:
Ethyl 4-iodo-1H-pyrazole-5-carboxylate is used as a precursor in the synthesis of pharmacologically active compounds, contributing to the development of new drugs with potential therapeutic benefits.
Used in the Preparation of Functionalized Pyrazole Derivatives:
Ethyl 4-iodo-1H-pyrazole-5-carboxylate is also used in the preparation of various functionalized pyrazole derivatives, which can have diverse applications in different chemical and pharmaceutical industries.
Used in Research and Development:
Ethyl 4-iodo-1H-pyrazole-5-carboxylate is utilized in research and development settings to explore its potential applications and to understand its chemical properties and reactivity, which can lead to the discovery of new uses and applications in various industries.

Upstream product

• 5932-27-4 ethyl 1H-pyrazole-3-carboxylate 
• 623-47-2 propynoic acid ethyl ester 
• 21056-77-9 2H-pyrazole-3-carboxylic acid ethyl ester 

Downstream Products

• 1355249-29-4 ethyl 4-iodo-1-(4-methoxybenzyl)-1H-pyrazole-3-carboxylate 
• 1355249-30-7 C₂₀H₂₇BN₂O₅ 
• 1355249-32-9 C₂₅H₃₀N₄O₇S 
• 1355249-46-5 C₂₄H₂₈N₄O₆S 
• 1355249-53-4 C₂₃H₂₆N₄O₆S 
• 1355249-54-5 C₃₂H₃₉N₅O₇S 
• 1355336-09-2 ethyl 4-iodo-1-(4-methoxybenzyl)-1H-pyrazole-5-carboxylate 
• 1355336-10-5 4-iodo-1-(4-methoxybenzyl)-1H-pyrazole-3-carboxylic acid 
• 1355336-11-6 4-iodo-1-(4-methoxybenzyl)-1H-pyrazole-5-carboxylic acid 
• 1354705-42-2 ethyl 4-iodo-1-methyl-1H-pyrazole-5-carboxylic acid 
• 6647-98-9 4-iodo-1-methyl-1H-pyrazole-3-carboxylic acid 

Relevant academic research and scientific papers

DIHYDROPYRAZOLOPYRAZINONE DERIVATIVES

PROBLEM TO BE SOLVED: To provide compounds useful as therapeutic agents for disease involving metabotropic glutamate receptor subtype 2 and/or metabotropic glutamate receptor subtype 3. SOLUTION: The invention provides compounds represented by formula (1)

TRICYCLIC COMPOUND SERVING AS IMMUNOMODULATOR

Provided are compounds of formula I and formula II or pharmaceutically acceptable salts of the compounds and pharmaceutical compositions thereof. The compounds of formula I and formula II or the pharmaceutically acceptable salts of the compounds provide indole 2,3-dioxygenase (IDO) inhibitory activity and are capable of treating IDO-mediated immunosuppressive diseases, such as infectious diseases or cancer.

CYANOPYRROLIDINES AS DUB INHIBITORS FOR THE TREATMENT OF CANCER

The present invention relates to novel compounds and method for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C- terminal hydrolase L1 (UCHL1) and ubiquitin C-terminal hydrolase 30 or ubiquitin specific peptidase 30 (USP30). The invention further relates to the use of DUB inhibitors in the treatment of cancer and conditions involving mitochondrial dysfunction. Compounds of the invention include compounds having the formula (I) or a pharmaceutically acceptable salt thereof, wherein R1,R2,R3,R4,R5,R6,R7,R8 and R9 are as defined herein.

PYRROLOPYRIMIDINE COMPOUND

The present application relates to the field of pharmaceutical chemistry, and in particular, to a pyrrolopyrimidine compound represented by general formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof. The present invention further relates to a method for preparing the pyrrolopyrimidine compound represented by general formula (I), pharmaceutical compositions and an application of the pyrrolopyrimidine compound in treating diseases mediated by Janus Kinase.

Novel Compounds as Autotaxin Inhibitors and Pharmaceutical Compositions Comprising the Same

The present invention relates to a novel autotaxin inhibitor compound for preventing and treating disease or symptoms due to an increase in concentration of lysophosphatidic acid or activation of autotaxin. The present invention further relates to a pharmaceutical composition containing the same. The novel compound of the present invention is an autotaxin inhibitor which inhibits production of lysophosphatidic acid, and thus is useful for treating or preventing cardiovascular disease, cancer, metabolic disease, kidney disease, liver disease, inflammatory diseases, nervous disease, respiratory disease, desmoid disease, eye disease, cholestatic symptoms, other types of chronic pruritus or acute, or chronic rejection of transplanted organs.COPYRIGHT KIPO 2017

SUBSTITUTED TRICYCLIC HERTEOCYCLIC COMPOUNDS AND USE THEREOF

Provided are a substituted tricyclic herteocyclic compound of formula I or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt, ester or a prodrug thereof, a pharmaceutical composition including the same and uses thereof. The substituted tricyclic herteocyclic compounds and the pharmaceutical compositions comprising the compounds disclosed herein can be used for treating a disorder caused by at least one of cancer and neurodegenerative diseases. Further the compounds and the pharmaceutical compositions comprising the compounds disclosed herein can be also used for preventing or treating a disorder caused by, associated with or accompanied by any abnormal kinase activity.

HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS

The present application relates to certain halo-substituted piperidine compounds, pharmaceutical compositions containing them, and methods of using them, including methods for treating substance addiction, panic disorder, anxiety, post-traumatic stress disorder, pain, depression, seasonal affective disorder, an eating disorder, or hypertension.

6,7-DIHYDROPYRAZOLO[1,5-A]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS

The present invention relates to novel 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one derivatives as negative allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 2 ("mGluR2"). The invention is also directed to pharmaceutical compositi

6,7-DIHYDROPYRAZOLO[1,5-A]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS

The present invention relates to novel 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one derivatives as negative allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 2 ("mGluR2"). The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention or treatment of disorders in which the mGluR2 subtype of metabotropic receptors is involved.

6,7-DIHYDROPYRAZOLO[1,5-α]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS

The present invention relates to novel 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one derivatives as negative allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 2 ("mGluR2"). The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention or treatment of disorders in which the mGluR2 subtype of metabotropic receptors is involved.